Regeneron Pharmaceuticals, Inc. has announced that the European Medicines Agency is reviewing the Marketing Authorization Application for a drug called linvoseltamab. This drug is meant to treat adult patients with relapsed/refractory multiple myeloma who have not responded to at least three prior therapies. The application is based on data from a pivotal Phase 1/2 trial.
Linvoseltamab is an experimental, bispecific antibody that is designed to connect B-cell maturation antigen on multiple myeloma cells with CD3-expressing T cells. This connection facilitates the activation of T-cell and kills cancer cells.
For more health news, visit rttnews.com.
